Comparison
Tesamorelin vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
901758-09-6
57773-63-4
Molecular weight
5135.83 g/mol
1311.45 g/mol
Half-life
0.4 h
3 h
Sequence
trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
Tesamorelin
Tesamorelin is an N-terminally modified 44-amino-acid version of human GHRH(1-44). A 3-hexenoyl modification protects against rapid dipeptidyl-peptidase-IV cleavage. Binding to the pituitary GHRH receptor stimulates endogenous pulsatile growth-hormone secretion and consequently hepatic IGF-1 production.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
2
4
of which in humans
2
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
3